Intec Pharma Ltd (NASDAQ:NTEC) Short Interest Update
Intec Pharma Ltd (NASDAQ:NTEC) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 3,000,000 shares, a decrease of 27.2% from the August 15th total of 4,120,000 shares. Based on an average daily volume of 7,680,000 shares, the days-to-cover ratio is currently 0.4 days.
Shares of Intec Pharma stock traded down $0.01 during trading on Wednesday, hitting $0.28. The stock had a trading volume of 116,338 shares, compared to its average volume of 6,119,656. Intec Pharma has a 12 month low of $0.13 and a 12 month high of $1.56. The firm’s fifty day simple moving average is $0.34 and its 200-day simple moving average is $0.29. The stock has a market cap of $20.70 million, a PE ratio of -0.31 and a beta of 0.77.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Analysts forecast that Intec Pharma will post -0.21 earnings per share for the current year.
A number of equities analysts have commented on the stock. HC Wainwright reissued a “neutral” rating on shares of Intec Pharma in a research note on Monday, August 17th. Zacks Investment Research raised shares of Intec Pharma from a “sell” rating to a “hold” rating in a report on Thursday, July 16th. Finally, Maxim Group reissued a “hold” rating on shares of Intec Pharma in a research note on Thursday, August 6th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $0.63.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Further Reading: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.